GILEAD SCIENCES, INC. Equity Securities, FV-NI, Unrealized Gain (Loss)
GILEAD SCIENCES, INC. (GILD) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $340.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-08-06
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was $340.00M, a 137.76% increase year-over-year.
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was $131.00M.
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was $203.00M.
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was $494.00M, a 92.22% increase year-over-year.
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was $404.00M.
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was -$284.00M.
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was -$60.00M.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $340.00M 10-Q · filed 2026-08-06 | $137.00M 10-Q · filed 2026-08-06 | $674.00M derived: sum of 3 quarters · filed 2026-08-06 | $1.17B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $131.00M 10-Q · filed 2026-05-07 | $334.00M derived: sum of 2 quarters · filed 2026-05-07 | $828.00M derived: sum of 3 quarters · filed 2026-05-07 | $971.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $203.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $697.00M derived: sum of 2 quarters · filed 2026-02-24 | $840.00M derived: sum of 3 quarters · filed 2026-08-06 | $404.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | $494.00M 10-Q · filed 2025-11-07 | $637.00M derived: sum of 2 quarters · filed 2026-08-06 | $201.00M 10-Q · filed 2025-11-07 | $72.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $143.00M 10-Q · filed 2026-08-06 | -$293.00M 10-Q · filed 2026-08-06 | -$422.00M derived: sum of 3 quarters · filed 2026-08-06 | -$165.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$436.00M 10-Q · filed 2026-05-07 | -$565.00M derived: sum of 2 quarters · filed 2026-05-07 | -$308.00M derived: sum of 3 quarters · filed 2026-05-07 | -$700.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$129.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $128.00M derived: sum of 2 quarters · filed 2026-02-24 | -$264.00M derived: sum of 3 quarters · filed 2026-02-24 | -$284.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $257.00M 10-Q · filed 2025-11-07 | -$135.00M derived: sum of 2 quarters · filed 2025-11-07 | -$155.00M 10-Q · filed 2025-11-07 | $39.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$392.00M 10-Q · filed 2025-08-07 | -$412.00M 10-Q · filed 2025-08-07 | -$218.00M derived: sum of 3 quarters · filed 2026-02-24 | -$346.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$15.00M 10-Q · filed 2025-05-07 | $174.00M derived: sum of 2 quarters · filed 2026-02-24 | $46.00M derived: sum of 3 quarters · filed 2026-02-24 | $115.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $189.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $61.00M derived: sum of 2 quarters · filed 2026-02-24 | $130.00M derived: sum of 3 quarters · filed 2026-02-24 | -$60.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$128.00M 10-Q · filed 2024-11-12 | -$59.00M derived: sum of 2 quarters · filed 2024-11-12 | -$249.00M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $69.00M 10-Q · filed 2024-08-08 | -$121.00M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |